<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158652</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 99-02</org_study_id>
    <nct_id>NCT00158652</nct_id>
  </id_info>
  <brief_title>Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC</brief_title>
  <official_title>Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <brief_summary>
    <textblock>
      This is a multicentric randomized phase III trial comparing conventional radiotherapy with
      concomitant chemotherapy versus accelerated radiotherapy with concomitant chemotherapy versus
      very accelerated radiotherapy in patients with stage III-IV head and neck squamous cell
      carcinoma. The main end point is the event free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric randomized phase III trial comparing conventional radiotherapy with
      concomitant chemotherapy (arm A) versus middle accelerated radiotherapy with concomitant
      chemotherapy (arm B) versus very accelerated radiotherapy alone (arm C) in patients with
      stage III-IV head and neck squamous cell carcinoma (HNSCC). The main end point is the event
      free survival.

      The treatments are

      Bras A : Conventional radiotherapy given once daily, delivering 70 Gy in 7 weeks (5 fractions
      of 2 Gy per week) and chemotherapy: 5FU : 600 mg/m²/d, Paraplatin : 70 mg/m²/d, D1-4 and
      D22-25 and D43-46

      Bras B: middle accelerated radiotherapy delivering 70 Gy in 6 weeks and chemotherapy: 5FU :
      600 mg/m²/d, Paraplatin : 70 mg/m²/d, D1-5 and D29-33

        -  first part : radiotherapy given once daily delivering 40 Gy in 4 weeks and 20 fractions
           of 2 Gy

        -  second part : radiotherapy given twice daily with &quot;concomitant boost&quot; delivering 30 Gy
           in 20 fractions in 2 weeks (1,5 Gy x 2 / day)

      Bras C: very accelerated radiotherapy given twice daily delivering 64.8 Gy in 3.5 weeks in 36
      fractions of 1.8 Gy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (event=progression, relapse, death from any cause)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco regional control</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>early and late</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">840</enrollment>
  <condition>Oral Cancer</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <condition>Larynx Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional radiotherapy 70 Gy in 7 weeks</intervention_name>
    <description>2 gy per fraction, 1 fraction per day, 5 fractions per week</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>middle accelerated radiotherapy 70 Gy in 6 weeks</intervention_name>
    <description>5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>very accelerated radiotherapy 64.8 Gy in 3.5 weeks</intervention_name>
    <description>2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU, Paraplatin</intervention_name>
    <description>5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Squamous cell carcinoma of oral cavity, oropharynx, hypopharynx or larynx

          -  Stage III-IV (UICC 1997): T2, T3 or T4 with N0-N3 or T0 with N2-N3

          -  Not resectable

          -  Karnofsky PS &gt;= 70

          -  Renal/liver/cardiac functions and blood counts compatible with the use of paraplatin
             and 5-FU

          -  Informed consent signed

        Exclusion Criteria:

          -  Distant metastasis

          -  Contra-indication to concomitant chemotherapy

          -  History of cancer

          -  History of head and neck radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Bourhis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Calais</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37 044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gortec.org</url>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

